Essential Clinical Trial Resources for Foreign Healthcare Companies in China — China represents the world’s second-largest pharmaceutical market and the fastest-growing clinical trial environment, yet foreign healthcare companies face a complex regulatory landscape that requires mastery of distinct digital platforms, approval portals, and compliance frameworks. Navigating clinical trials in China demands familiarity with a specialized ecosystem of resources — from the Chinese Clinical Trial Register (ChiCTR) and the Human Genetic Resources (HGR) Administration platform to the Center for Drug Evaluation (CDE) IND submission portal and the China Food and Drug Administration (CFDI) inspection database. This comprehensive resource guide provides foreign healthcare companies with an authoritative map of every essential clinical trial tool, platform, regulatory body, and fee schedule needed to design, register, obtain approval for, and execute clinical trials in China — all in full compliance with the Drug Administration Law, the HGR Regulations, and the Good Clinical Practice (GCP) standards enforced by the National Medical Products Administration (NMPA).
What This Resource Covers
This resource is a complete reference guide for foreign pharmaceutical companies, biotechnology firms, CROs (Contract Research Organizations), and academic sponsors planning or conducting clinical trials in the People’s Republic of China. It covers the full lifecycle of clinical trial operations for foreign entities: trial registration obligations, regulatory submission portals, ethics committee coordination, human genetic resource compliance, insurance requirements, investigator-initiated trial (IIT) frameworks, inspection readiness, and contractual templates. Each resource entry includes the official Chinese regulatory authority, the governing legislation, specific timelines (including the critical 60-working-day IND review clock and the 30-day HGR approval window), applicable fees, and step-by-step access instructions. Whether you are filing your first IND as a foreign sponsor or expanding an existing China development program, this guide equips your team with the precise digital tools and procedural knowledge required to succeed.
Core Resources
| Resource Name | Description | Key Details | Access Info |
|---|---|---|---|
| ChiCTR — Chinese Clinical Trial Register (中国临床试验注册中心) |
The official WHO primary registry for all clinical trials conducted in China. Mandatory public registration for interventional trials, observational studies, and certain real-world evidence studies before first participant enrollment. |
• Registration required within 21 days of first participant enrollment • Unique ChiCTR ID issued upon approval (format: ChiCTR2000XXXXX) • Posting to WHO ICTRP portal automatically upon registration • Updates and results submission required within 12 months of trial completion • Governed by ICMJE and WHO registration standards • Chinese and English bilingual interface |
URL: www.chictr.org.cn Registration: Free Language: Chinese (primary), English Support: Online helpdesk and email support Sponsor requirement: All foreign sponsors must register before enrollment |
| HGR Approval Platform — Human Genetic Resources Administration (科技部人类遗传资源管理平台) |
The digital submission and approval system operated by the Ministry of Science and Technology (MOST, 科技部) for all collection, transfer, and export of Chinese human genetic resources related to clinical trials. A mandatory approval gateway for any foreign entity involved in clinical research using Chinese biospecimens or genetic data. |
• Approval timeline: 30 working days for standard HGR applications • Streamlined filing (备案) available for IVD reagent trials and certain low-risk studies (20 working days) • International transfer of HGR samples requires separate approval (60 working days) • Penalties for non-compliance: up to RMB 10 million (approx. USD 1.4 million) plus suspension of trial • Governed by the HGR Regulations (effective July 1, 2023) and the 2024 Implementation Rules • Bilateral science and technology cooperation agreement required |
URL: grants.most.gov.cn Registration: Free (entity registration required) Approval fees: RMB 2,000–10,000 (approx. USD 280–1,400) depending on application type Language: Chinese only (English translations accepted as supplementary) Annual renewal: Required for registered entities |
| CDE IND Submission Portal — Center for Drug Evaluation (国家药品监督管理局药品审评中心) |
The primary electronic submission portal for Investigational New Drug (IND) applications to the NMPA via the CDE. All foreign sponsors must submit IND applications through this portal to initiate clinical trials in China. Accepts both chemical drugs (Class 1–5) and biologic products (Class 1–3). |
• IND decision timeline: 60 working days from acceptance (silence = approval) • If no rejection notice within 60 working days, the IND is deemed approved • Acceptance review: 5 working days • Technical review: 55 working days • Supplementary information deadline: 4 working days if requested • Clinical trial protocol, Investigator’s Brochure, and IB must be in Chinese • ECTD (eCTD) format required since 2023 for new submissions |
URL: www.cde.org.cn Registration: Free (CDE acceptance account via NMPA) Submission fee: RMB 200,000–450,000 (approx. USD 28,000–63,000) per IND (Class 1 new drugs) Language: Chinese (mandatory; English summaries permitted for supplementary materials) Technical support: CDE hotline +86-10-68585566 |
| China Ethics Committee Database / IEC Directory (药物临床试验伦理委员会名录) |
A searchable database of Institutional Ethics Committees (IECs) and Independent Ethics Committees (IRBs) registered and recognized by the NMPA for clinical trial review. Foreign sponsors must obtain ethics approval from a qualified IEC prior to initiating any trial at a Chinese site. |
• Ethics review timeline: 20–45 working days (initial review) • Expedited review available for minimal-risk studies (10–15 working days) • Centralized ethics review now accepted for multi-site trials (pilot policy) • Renewal every 12 months required for ongoing trials • Committee composition must include at least 5 members, including at least 1 non-scientific member and 1 independent member • All ethics committee members must complete NMPA GCP training |
URL: www.cde.org.cn/ethics Access: Free, public directory Language: Chinese Direct contact: Each hospital/institution IEC listed with address and phone Registration: Ethics committees self-register with CDE |
| Clinical Trial Insurance Requirements & Guidelines (临床试验保险要求与指南) |
The mandatory insurance framework governing clinical trial liability coverage for foreign sponsors conducting trials in China. Under the Drug Administration Law and GCP regulations, all sponsors — including foreign entities — must carry clinical trial insurance that covers participant injury or harm arising from trial participation. |
• Minimum coverage: Not statutorily fixed but commonly RMB 10–50 million (USD 1.4–7 million) per trial • Insurance must be placed with a licensed Chinese insurer (PICC, CPIC, Ping An, or Taikang are common) • Policy must cover all trial sites and all enrolled participants • Certificate of Insurance must be submitted with IND application • Premiums typically range from 2–5% of coverage amount depending on trial phase and risk • No-fault compensation clause strongly recommended (market standard) • Coverage period: From first participant enrollment through last follow-up visit plus extended reporting period |
Guidelines: NMPA GCP Chapter 7 (Sponsor Obligations) Sample insurance documents: Available through DIA China and industry associations Language: Chinese policy required; English translations accepted as supplementary Premium estimate: RMB 200,000–2,500,000 (USD 28,000–350,000) per trial depending on phase and size |
| CRO Directory — DIA China & 中国药物研发协会 (CRO行业名录) |
Comprehensive directories of qualified Contract Research Organizations (CROs) registered and operational in China, maintained by the Drug Information Association (DIA) China Chapter and the China Pharmaceutical R&D Association. Essential resource for foreign sponsors seeking local clinical operations partners, site management, regulatory affairs support, and data management services. |
• DIA China membership: >3,000 individual members, >200 corporate members • Directory categories: Full-service CROs, Site Management Organizations (SMOs), Biostatistics CROs, Regulatory CROs, and Data Management CROs • Due diligence resources: Audit history, GCP inspection record, international certifications (ISO 9001, ISO 27001) • Tier 1 CROs: IQVIA China, Labcorp (Covance) China, WuXi AppTec, Medpace China, BeiGene Clinical Operations • Tier 2 CROs: Hangzhou Tigermed, Dizal Pharmaceutical, Fountain Medical Development, ClinChoice • Annual DIA China Annual Meeting (typically June, Shanghai) — major networking platform |
URL: www.diaglobal.org (global) / DIA China Chapter DIA membership fee: USD 295/year (individual), USD 6,500–25,000/year (corporate) CRO Directory access: Free for DIA members; RMB 5,000 (USD 700) for non-members Language: English and Chinese Due diligence reports: Available through DIA China separately |
| IIT (Investigator-Initiated Trial) Guidelines (研究者发起的临床试验指南) |
The regulatory framework and operational guidelines for Investigator-Initiated Trials (IITs) in China, which are increasingly important for foreign companies collaborating with Chinese principal investigators on exploratory, mechanism-of-action, or post-marketing studies. Distinguished from sponsor-initiated INDs by regulatory pathway and approval requirements. |
• IITs conducted under NMPA 2024 IIT Management Guidelines (effective March 2024) • No separate IND required if: (a) using approved drug, (b) within approved indication, (c) no additional safety risk • If any criteria not met: IIT must follow full IND pathway via CDE • IIT sponsor responsibility rests with the investigator/hospital — but foreign companies providing drug or funding are co-responsible • Funding disclosure mandatory: foreign funding must be declared and may trigger HGR review • Data from IITs can be used for label expansion submissions if GCP-compliant • IITs require: IEC/IRB approval + institutional approval + ChiCTR registration |
Guidelines: NMPA IIT Guidelines (2024), accessible via www.nmpa.gov.cn Registration: Free (ChiCTR registration costs apply for post-approval amendments) IEC fee: RMB 5,000–20,000 (USD 700–2,800) per review Language: Chinese (study documents must be in Chinese) |
| CFDI Clinical Trial Inspection Database (国家药品监督管理局食品药品审核查验中心 — CFDI检查数据库) |
The official database maintained by the Center for Food and Drug Inspection (CFDI) of the NMPA, containing historical clinical trial inspection records, inspection findings, and enforcement actions. Foreign sponsors must use this database for due diligence on CROs and trial sites, and to prepare for mandatory CFDI inspections. |
• Routine GCP inspections: Conducted every 3–5 years per site • For-cause inspections: Triggered by safety signals, protocol deviations, or data integrity concerns • Inspection notification: Typically 5–10 working days in advance • Inspection duration: 3–10 working days depending on scope • Common findings: Informed consent deficiencies (35% of inspections), adverse event reporting gaps (28%), and data source verification issues (22%) • Foreign sponsor inspections: NMPA now conducts overseas inspections at foreign sponsor sites (9 inspections in 2024) • Inspection results posted to database within 30 working days of inspection conclusion |
URL: www.cfdi.org.cn Access: Free, public database Language: Chinese Search filters: By drug name, by site, by inspection type, by year Inspection report request: RMB 500 (USD 70) per official copy |
| Clinical Trial Agreement (CTA) Templates & Standard Clauses (临床试验合同模板) |
Standardized CTA templates and model clauses recognized by Chinese hospitals, academic medical centers, and the NMPA for clinical trial contracting between foreign sponsors and Chinese investigator sites. Proper CTA execution is a prerequisite for ethics committee approval and site initiation. |
• Standard CTA review timeline: 4–8 weeks (site-by-site) • Key clauses: Indemnification, insurance, publication rights (first right of refusal for sponsor), data ownership (sponsor owns trial data; site owns source records), IP allocation, confidentiality, termination for cause • Mandatory Chinese governing law clause: All CTAs must specify PRC law as governing law • Dispute resolution: CIETAC (China International Economic and Trade Arbitration Commission) arbitration recommended • Budget structure: Per-patient cost + site overhead (typically 15–25%) + startup fees • Payment terms: Milestone-based (enrollment + completion of each phase) or per-visit |
Templates: Available through DIA China, China Medical University (CMU), and Peking University Clinical Research Institute Legal review: RMB 10,000–50,000 (USD 1,400–7,000) per CTA (law firm fees) Language: Bilingual (Chinese and English); Chinese version prevails in case of conflict Notarization: Foreign sponsor signatures may require notarization |
| 60/90-Day IND Review Timeline & Tracking Dashboard (IND审评时限跟踪平台) |
A regulatory tracking resource that enables foreign sponsors to monitor the CDE’s IND review progress against the statutory 60-working-day clock (chemical drugs) and 90-working-day clock (biologics and innovative traditional Chinese medicines). Critical for trial timeline planning and resource allocation. |
• Chemical drugs: 60 working days from acceptance (tacit approval if no rejection) • Biologics / innovative TCM: 90 working days from acceptance • Priority review: 40 working days (for breakthrough therapies, rare disease drugs) • Clock-stop provisions: If CDE requests supplementary information, the review clock stops until submission • Supplementary information deadline: 4 working days (failure = application withdrawal) • Tracking available through CDE acceptance number (受理号) • 2024 average actual review time: 48 working days (chemical IND), 72 working days (biologic IND) |
URL: www.cde.org.cn/review Access: Free (public tracking database) Language: Chinese Mobile: CDE WeChat mini-program available for real-time tracking Alert setup: Email notifications available for status changes (registration required) |
How to Use These Resources — 5 Expert Tips
- Register with ChiCTR before first patient enrollment — not after. Many foreign sponsors underestimate the 21-day registration window. The ChiCTR registration process typically takes 5–10 working days from submission to ID issuance, including administrative review and data validation. Submit your trial protocol, statistical analysis plan, and informed consent form simultaneously to avoid clock delays. Remember that ChiCTR registration must be completed before the first participant is enrolled — not within 21 days after enrollment. This is a common compliance gap that can result in publication penalties and ICMJE rejection.
- Initiate HGR approval 60 working days before your planned IND submission. The HGR approval process (30 working days for standard applications) runs parallel to, but independently from, the CDE IND review. Foreign sponsors frequently make the mistake of sequencing these processes instead of running them concurrently. Begin your HGR entity registration at least 8 weeks before your planned IND submission. Prepare your HGR application dossier — including the bilateral science and technology cooperation agreement, the informed consent form (HGR-compliant version), and the ethical review approval — before the CDE submission clock starts. For trials involving international transfer of biospecimens, budget 60 additional working days for the separate international transfer approval.
- Use the CFDI inspection database as a CRO/site pre-qualification tool, not a post-audit reference. Before selecting a CRO or investigator site, run a comprehensive CFDI database search on the entity’s full inspection history over the past 5 years. Focus on: (a) the number of for-cause inspections versus routine inspections; (b) the severity of findings (critical vs. major vs. minor); (c) the time to closure of corrective and preventive action (CAPA) plans; and (d) whether any enforcement actions (warning letters, suspension, or disqualification) were issued. A site with three or more critical findings in the last two inspection cycles should trigger enhanced due diligence or elimination from consideration.
- Draft your CTA with the Chinese-language version controlling — and budget 8–12 weeks for negotiation. Foreign sponsors commonly underestimate CTA negotiation timelines in China. Unlike many jurisdictions where the sponsor’s standard template prevails, Chinese academic medical centers and hospitals have their own mandatory CTA templates that often include provisions unfavorable to sponsors (e.g., unlimited liability, ambiguous IP allocation, or publication veto rights). Engage Chinese counsel experienced in clinical trial contracting at least 12 weeks before your planned site initiation visit. Key negotiating points: (a) cap sponsor indemnification to the insurance coverage amount; (b) ensure the sponsor retains ownership of trial data; (c) confirm the site’s publication rights are subject to a 90-day sponsor review period; and (d) include a specific performance clause for site enrollment commitments.
- Track the CDE 60/90-day clock daily and prepare response materials in advance of clock-stop events. The CDE review clock is unforgiving. If the CDE issues a supplementary information request on working day 45 of a 60-day review, you have exactly 4 working days to respond — or the application is withdrawn and you must resubmit from scratch (restarting the 60-day clock and incurring a new IND submission fee). Prepare a pre-emptive response package before submission: anticipate the most common CDE queries (dosing rationale, ethnic sensitivity analysis, manufacturing process validation, and preclinical toxicology findings) and have Chinese-language responses pre-drafted with supporting data ready for upload. Assign a dedicated regulatory affairs team member to check the CDE tracking portal daily — do not rely on email notifications, which can be delayed by 24–48 hours.
Fee Schedule — Resource Costs at a Glance
| Resource / Service | Fee (RMB) | Fee (USD Approx.) | Notes |
|---|---|---|---|
| ChiCTR Clinical Trial Registration | Free | Free | No registration fee; post-registration amendment fee applies for protocol changes (RMB 500–2,000) |
| HGR Approval (Standard Application) | RMB 5,000–10,000 | USD 700–1,400 | International transfer applications: RMB 10,000–20,000; streamlined filing (备案): RMB 2,000–5,000 |
| CDE IND Submission (Class 1 New Drug) | RMB 200,000–450,000 | USD 28,000–63,000 | Generic drug IND: RMB 150,000–250,000; Biologic IND: RMB 350,000–500,000; Priority review: no additional fee |
| Ethics Committee / IEC Review | RMB 5,000–20,000 | USD 700–2,800 | Expedited review: RMB 8,000–15,000; Centralized review (multi-site): RMB 10,000–25,000 |
| Clinical Trial Insurance (per trial, Phase I–III) | RMB 200,000–2,500,000 | USD 28,000–350,000 | Premium depends on phase (Phase I highest), number of participants, and therapeutic area (oncology premium 1.5–2x standard) |
| CTA Legal Review & Negotiation (per site) | RMB 10,000–50,000 | USD 1,400–7,000 | Includes Chinese law firm review, translation, and negotiation; multi-site discounts available (10–15% per additional site) |
| DIA China CRO Directory Access (Non-Member) | RMB 5,000 | USD 700 | Free for DIA individual members (USD 295/year) and included in corporate membership (USD 6,500–25,000/year) |
Note: All fees are estimates as of 2025 and are subject to change. Foreign sponsors should confirm current fees with the relevant authority or service provider at the time of application. Exchange rate: approximately 1 USD = 7.15 RMB.
Ready to Execute Your China Clinical Trial Strategy?
Navigating China’s clinical trial regulatory ecosystem demands more than just knowing which platforms exist — it requires precision in timing, accuracy in documentation, and fluency in the interplay between CDE, HGR, ChiCTR, and CFDI processes. A single misstep in registration timing, a missing HGR approval, or a non-compliant CTA clause can delay your trial by 6–12 months and cost hundreds of thousands of dollars in wasted resources.
CG Advisors Clinical Trial Navigation Service provides end-to-end regulatory support for foreign healthcare companies conducting clinical trials in China. Our team of former NMPA reviewers, CDE regulatory scientists, and China-qualified clinical operations experts will:
- Conduct a comprehensive pre-submission readiness assessment against CDE, HGR, and ChiCTR requirements
- Prepare and submit your IND dossier, HGR application, and ethics committee package
- Negotiate CTAs with top-tier Chinese hospital sites on your behalf
- Provide real-time CDE review clock tracking with escalation protocols for clock-stop events
- Coordinate CFDI inspection readiness including mock inspections and CAPA preparation
Contact us today for a complimentary 30-minute China clinical trial strategy consultation:
Email: clinicaltrials@cgadvisors.com
Phone (China): +86-21-8017-9200
Phone (International): +1-212-400-7999
WeChat: CGAdvisors_CT
CG Advisors — China Healthcare Practice
Your trusted partner for clinical trial excellence in China since 2012.
